Covalent Modifier Discovery Using Hydrogen/Deuterium Exchange-Mass Spectrometry

被引:0
作者
Kojima, Hiroyuki [1 ]
Yanagi, Ryota [1 ]
Higuchi, Eri [1 ]
Yoshizawa, Mami [1 ]
Shimodaira, Tomoyuki [1 ]
Kumagai, Misaki [1 ]
Kyoya, Tatsuhiro [1 ]
Sekine, Miyu [1 ]
Egawa, Daichi [1 ]
Ohashi, Nami [1 ]
Ishida, Hiroaki [1 ]
Yamamoto, Keiko [1 ]
Itoh, Toshimasa [1 ]
机构
[1] Showa Pharmaceut Univ, Lab Drug Design & Med Chem, Machida, Tokyo 1948543, Japan
关键词
PPAR-GAMMA; DRUG DISCOVERY; LIGAND; INHIBITORS; ANTAGONIST; RECEPTORS; CANCER; ACID;
D O I
10.1021/acs.jmedchem.2c01986
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Covalent ligands are generally filtered out of chemical libraries used for high-throughput screening, because electrophilic functional groups are considered to be pan-assay interference compounds (PAINS). Therefore, screening strategies that can distinguish true covalent ligands from PAINS are required. Hydrogen/deuterium-exchange mass spectrometry (HDX-MS) is a powerful tool for evaluating protein stability. Here, we report a covalent modifier screening approach using HDX-MS. In this study, HDX-MS was used to classify peroxisome proliferatoractivated receptor gamma (PPAR gamma) and vitamin D receptor ligands. HDX-MS could discriminate the strength of ligand-protein interactions. Our HDX-MS screening method identified LT175 and nTZDpa, which can bind concurrently to the PPAR gamma ligand-binding domain (PPAR gamma-LBD) with synergistic activation. Furthermore, iodoacetic acid was identified as a novel covalent modifier that stabilizes the PPAR gamma-LBD.
引用
收藏
页码:4827 / 4839
页数:13
相关论文
共 56 条
  • [1] PHENIX: a comprehensive Python']Python-based system for macromolecular structure solution
    Adams, Paul D.
    Afonine, Pavel V.
    Bunkoczi, Gabor
    Chen, Vincent B.
    Davis, Ian W.
    Echols, Nathaniel
    Headd, Jeffrey J.
    Hung, Li-Wei
    Kapral, Gary J.
    Grosse-Kunstleve, Ralf W.
    McCoy, Airlie J.
    Moriarty, Nigel W.
    Oeffner, Robert
    Read, Randy J.
    Richardson, David C.
    Richardson, Jane S.
    Terwilliger, Thomas C.
    Zwart, Peter H.
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 : 213 - 221
  • [2] Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity
    Anderson, Kimberly E.
    To, Milton
    Olzmann, James A.
    Nomura, Daniel K.
    [J]. ACS CHEMICAL BIOLOGY, 2017, 12 (10) : 2522 - 2528
  • [3] Proteome-wide covalent ligand discovery in native biological systems
    Backus, Keriann M.
    Correia, Bruno E.
    Lum, Kenneth M.
    Forli, Stefano
    Horning, Benjamin D.
    Gonzalez-Paez, Gonzalo E.
    Chatterjee, Sandip
    Lanning, Bryan R.
    Teijaro, John R.
    Olson, Arthur J.
    Wolan, Dennis W.
    Cravatt, Benjamin F.
    [J]. NATURE, 2016, 534 (7608) : 570 - +
  • [4] New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
    Baell, Jonathan B.
    Holloway, Georgina A.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (07) : 2719 - 2740
  • [5] THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY
    BAILEY, S
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 : 760 - 763
  • [6] DPP-4 inhibitors and their potential role in the management of type 2 diabetes
    Barnett, A.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (11) : 1454 - 1470
  • [7] Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies
    Bauer, Renato A.
    [J]. DRUG DISCOVERY TODAY, 2015, 20 (09) : 1061 - 1073
  • [8] Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator
    Berger, JP
    Petro, AE
    Macnaul, KL
    Kelly, LJ
    Zhang, BB
    Richards, K
    Elbrecht, A
    Johnson, BA
    Zhou, GC
    Doebber, TW
    Biswas, C
    Parikh, M
    Sharma, N
    Tanen, MR
    Thompson, GM
    Ventre, J
    Adams, AD
    Mosley, R
    Surwit, RS
    Moller, DE
    [J]. MOLECULAR ENDOCRINOLOGY, 2003, 17 (04) : 662 - 676
  • [9] High-throughput crystallography for lead discovery in drug design
    Blundell, TL
    Jhoti, H
    Abell, C
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) : 45 - 54
  • [10] A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat
    Brown, KK
    Henke, BR
    Blanchard, SG
    Cobb, JE
    Mook, R
    Kaldor, I
    Kliewer, SA
    Lehmann, JM
    Lenhard, JM
    Harrington, WW
    Novak, PJ
    Faison, W
    Binz, JG
    Hashim, MA
    Oliver, WO
    Brown, HR
    Parks, DJ
    Plunket, KD
    Tong, WQ
    Menius, JA
    Adkison, K
    Noble, SA
    Willson, TM
    [J]. DIABETES, 1999, 48 (07) : 1415 - 1424